AbbVie announced the European Commission, or EC, approved Rinvoq and 15 mg and 30 mg as the first oral Janus Kinase, or JAK, inhibitor for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABBV:
